Tamiflu Sales Boost Roche Earnings, As Genentech Merger Is Defended
This article was originally published in The Pink Sheet Daily
Executive Summary
Mid single-digit sales growth predicted for 2010.
You may also be interested in...
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Roche Wins Genentech After Months-Long Battle
The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.